Manchester Capital Management’s Marvell Technology MRVL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$94.7K Buy
318
+105
+49% +$21.1K 0.01% 395
2026
Q1
$21.1K Buy
213
+116
+120% +$9.74K ﹤0.01% 667
2025
Q4
$8.24K Sell
97
-1,275
-93% -$112K ﹤0.01% 823
2025
Q3
$115K Sell
1,372
-918
-40% -$67.6K 0.02% 393
2025
Q2
$177K Sell
2,290
-333
-13% -$20.8K 0.02% 360
2025
Q1
$161K Buy
2,623
+499
+23% +$48.4K 0.02% 364
2024
Q4
$235K Hold
2,124
0.03% 311
2024
Q3
$153K Buy
2,124
+475
+29% +$32.8K 0.02% 372
2024
Q2
$115K Buy
1,649
+129
+8% +$9.04K 0.01% 402
2024
Q1
$108K Hold
1,520
0.01% 396
2023
Q4
$91.7K Hold
1,520
0.01% 367
2023
Q3
$82.3K Hold
1,520
0.01% 370
2023
Q2
$90.9K Hold
1,520
0.01% 363
2023
Q1
$65.8K Buy
+1,520
New +$64K 0.01% 399

Other funds holding MRVL

Manchester Capital Management's MRVL Position: Q2 2026 in Review

Manchester Capital Management increased its Marvell Technology (MRVL) stake by 49% in Q2 2026, buying an estimated $21.1K and bringing the position to 318 shares worth $94.7K. The position accounts for 0.01% of the portfolio, ranked #395.

Manchester Capital Management first reported a position in MRVL in Q1 2023 and has held it in 14 quarters since. The position peaked at $235K in Q4 2024. 2,221 funds tracked by Wall St. Rank hold MRVL as of Q2 2026.

  • Manchester Capital Management held 318 shares of Marvell Technology worth $94.7K as of Q2 2026.
  • Manchester Capital Management bought 105 Marvell Technology shares in Q2 2026, an estimated $21.1K.
  • Marvell Technology made up 0.01% of Manchester Capital Management's portfolio in Q2 2026, its #395 holding.
  • Manchester Capital Management first reported a position in Marvell Technology in Q1 2023 and has held it in 14 quarters since.
  • Manchester Capital Management's Marvell Technology position peaked at $235K in Q4 2024.
  • 2,221 funds tracked by Wall St. Rank held Marvell Technology as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.